Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying—the Road to Manufacturing Scale

References

1. 1.↵
   1. Bowen M.,
   2. Turok B.,
   3. Maa Y.-F.

   Spray drying of monoclonal antibodies: investigating powder-based biologic drug substance bulk storage. Drying Technol. 2013, 31 (13–14), 1441–1450.

   OpenUrlGoogle Scholar
2. 2.↵
   1. Broadhead J.,
   2. Rouan S. K.,
   3. Hau I.,
   4. Rhodes C. T.

   The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J. Pharm. Pharmacol. 1994, 46 (6), 458–467.

   OpenUrlPubMedGoogle Scholar
3. 3.↵
   1. Maury M.,
   2. Murphy K.,
   3. Kumar S.,
   4. Mauerer A.,
   5. Lee G.

   Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur. J. Pharm. Biopharm. 2005, 59 (2), 251–261.

   OpenUrlPubMedGoogle Scholar
4. 4.↵
   1. Maa Y.-F.,
   2. Costantino H. R.,
   3. Nguyen P. A.,
   4. Hsu C. C.

   The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm. Dev. Technol. 1997, 2 (3), 213–223.

   OpenUrlPubMedGoogle Scholar
5. 5.↵
   1. Andya J. D.,
   2. Maa Y.-F.,
   3. Costantino H. R.,
   4. Nguyen P.-A.,
   5. Dasovich N.,
   6. Sweeney T. D.,
   7. Hsu C. C.,
   8. Shire S. J.

   The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 1999, 16 (3), 350–358.

   OpenUrlCrossRefPubMedGoogle Scholar
6. 6.↵
   1. Costantino H. R.,
   2. Andya J. D.,
   3. Nguyen P.-A.,
   4. Dasovich N.,
   5. Sweeney T. D.,
   6. Shire S. J.,
   7. Hsu C. C.,
   8. Maa Y.-F.

   The effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 1998, 87 (11), 1406–1411.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
7. 7.↵
   1. Schule S.,
   2. Schultz-Fademrecht T.,
   3. Garidel P.,
   4. Bechtold-Peters K.,
   5. Frieb W.

   Stabilization of IgG1 in spray-dried powders for inhalation. Eur. J. Pharm. Biopharm. 2008, 69 (3), 793–807.

   OpenUrlPubMedGoogle Scholar
8. 8.↵
   1. Maury M.,
   2. Murphy K.,
   3. Kumar S.,
   4. Shi L.,
   5. Lee G.

   Effects of process variables on the powder yield of spray-dried trehalose on a laboratory spray dryer. Eur. J. Pharm. Biopharm. 2005, 59 (3), 565–573.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
9. 9.↵
   1. Andya J. D.,
   2. Hsu C. C.,
   3. Shire S. J.

   Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 2003, 5 (2), 21–31.

   OpenUrlGoogle Scholar
10. 10.↵
    1. Jovanovic N.,
    2. Bouchard. A.,
    3. Hofland G. W.,
    4. Witkamp G. J.,
    5. Crommelin D. J.,
    6. Jiskoot W.

    Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying. Eur. J. Pharm. Sci. 2006, 27 (4), 336–345.

    OpenUrlPubMedGoogle Scholar
11. 11.↵
    1. Jain N. K.,
    2. Roy I.

    Effect of trehalose on protein structure. Protein Sci. 2009, 18 (1), 24–36.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
12. 12.↵
    1. Chang L.,
    2. Shepherd D.,
    3. Sun J.,
    4. Ouellette D.,
    5. Grant K. L.,
    6. Pikal M. J.

    Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J. Pharm. Sci. 2005, 94 (7), 1427–1444.

    OpenUrlPubMedGoogle Scholar
13. 13.↵
    1. Wang. Y.,
    2. Fei D.,
    3. Vanderlaan M.,
    4. Song A.

    Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7 (4), 335–345.

    OpenUrlCrossRefPubMedGoogle Scholar
14. 14.↵
    1. Park J. W.,
    2. Hongi T. K.,
    3. Carter P.,
    4. Asgarit H.,
    5. Guot L. Y.,
    6. Keller G. A.,
    7. Wirthii C.,
    8. Shalabyii R.,
    9. Kotrsi C.,
    10. Woodt W. I.,
    11. Papahadjopoulost D.,
    12. Benz C. C.

    Development of anti-p185IER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 1995, 92 (5), 1327–1331.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
15. 15.↵
    1. Gottschalk U.

    1. Li Y.,
    2. Kahn D. W.,
    3. Galperina O.,
    4. Blatter E.,
    5. Luo R.,
    6. Wu Y.,
    7. Zhang G.

    Development of a Platform Process for the Purification of Therapeutic Monoclonal Antibodies. In Process Scale Purification of Antibodies; Gottschalk U., Ed.; John Wiley & Sons: New York, 2011.

    Google Scholar
16. 16.↵
    1. Shire S. J.,
    2. Shahrokh Z.,
    3. Liu J.

    Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93 (6), 1390–1402.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
17. 17.↵
    1. Liu J.,
    2. Shire S. J.

    Reduced-viscosity concentrated protein formulations. U.S. Patent 8,142,776 B2, 2012.

    Google Scholar
18. 18.↵
    1. Liu J.,
    2. Shire S. J.

    High concentration antibody and protein formulations. U.S. Patent Application Publication US 2004/0197324 A1, 2004.

    Google Scholar
19. 19.↵
    1. Jezek J.,
    2. Darron N. J.,
    3. Derham B. K.,
    4. Royle N.,
    5. Simpson I.

    Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin. Drug Deliv. 2013, 10 (6), 811–828.

    OpenUrlPubMedGoogle Scholar
20. 20.↵
    1. Bowen M.,
    2. Armstrong N.,
    3. Maa Y.-F.

    Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J. Pharm. Sci. 2012, 101 (12), 4433–4443.

    OpenUrlPubMedGoogle Scholar
21. 21.↵
    1. Overcashier D. E.,
    2. Chan E. K.,
    3. Hsu C. C.

    Technical considerations in the development of prefilled syringes for protein products. Am. Pharm. Rev. 2006, 9 (7), 77–83.

    OpenUrlGoogle Scholar
22. 22.↵
    1. Sukumar M.,
    2. Doyle B. L.,
    3. Combs J. L.,
    4. Pekar A. H.

    Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 2004, 21 (7), 1087–1093.

    OpenUrlPubMedGoogle Scholar
23. 23.↵
    1. He F.,
    2. Woods C. E.,
    3. Trilisky E.,
    4. Bower K. M.,
    5. Litowski J. R.,
    6. Kerwin B. A.,
    7. Becker G. W.,
    8. Narhi L. O.,
    9. Razinkov V. I.

    Screening of monoclonal antibody formulation based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J. Pharm. Sci. 2011, 100 (4), 1330–1340.

    OpenUrlCrossRefPubMedGoogle Scholar
24. 24.↵
    1. Nony P.,
    2. Girard P.,
    3. Chabaud S.,
    4. Hessel L.,
    5. Thebault C.,
    6. Boissel J. P.

    Impact of osmolality on burning and sensation during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults. Vaccine 2001, 19 (27), 3645–3651.

    OpenUrlPubMedGoogle Scholar
25. 25.↵
    1. Zietkiewiz W.,
    2. Kostrewska E.,
    3. Gregor A.

    In vivo studies on the action on the tissue of the osmolality of parenterally administered drugs. Grzyby Drozdzopodobne 1977, 23, 869–870; The Ralph McElroy Translation Company: Austin, TX.

    OpenUrlGoogle Scholar
26. 26.↵
    1. Keele C. A.,
    2. Armsotrong D.

    Production of Pain by Hypertonic and Hypotonic Solutions. In Substance Producing Pain and Itch; Edward Arnold (Publishers), Ltd.: London, 1964; pp 67–72.

    Google Scholar
27. 27.↵
    1. Enliang L.,
    2. Yingmin W.

    A new collection theory of cyclone separators. AIChE J. 1989, 35 (4), 666–669.

    OpenUrlCrossRefWeb of ScienceGoogle Scholar